InvestorsHub Logo
Followers 13
Posts 1021
Boards Moderated 0
Alias Born 12/07/2011

Re: gotinearly post# 1403

Monday, 03/20/2017 9:52:21 PM

Monday, March 20, 2017 9:52:21 PM

Post# of 3630
Sorry I'm late for this but;

By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction."

How's this gonna play out?